Rosetta Genomics said Brian Markison has been named an observer of the company's board.
Pending shareholder approval, he will also become a director, the firm said.
Markison is currently chairman and CEO of King Pharmaceuticals, which was recently acquired by Pfizer. Previously, he held a variety of roles at Bristol-Myers Squibb, including president of oncology/virology and oncology therapeutics.